Astellas Pharma (OTCMKTS:ALPMY) Posts Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) issued its quarterly earnings results on Wednesday. The company reported $0.13 EPS for the quarter, reports. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. The business had revenue of $3.11 billion during the quarter.

Astellas Pharma Price Performance

Shares of OTCMKTS:ALPMY opened at $11.66 on Friday. The firm has a market cap of $21.10 billion, a price-to-earnings ratio of 55.53 and a beta of 0.37. Astellas Pharma has a 1 year low of $9.15 and a 1 year high of $13.14. The company has a current ratio of 0.90, a quick ratio of 0.72 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $11.94 and a 200 day simple moving average of $10.84.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.